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Hepatocellular carcinoma (HCC) is one of the most common causes of cancer 
death worldwide. Overexpression of epidermal growth factor receptor (EGFR) plays 
a vital role in tumor growth and progression. Inhibition of EGFR signaling not only 
reduces tumor cell growth, but may also serve as a potential radiation sensitizer in 
head and neck cancer, and glioblastoma. In this project, we investigated the role of 
tyrosine kinase inhibitor (TKI) and its radiation sensitizing effect on HCC. 
We studied the effect of an EGFR TKI, ZD 1839，on growth and radiation 
response in HCC cell lines (Hep3B，SNU-387, SNU-423, SNU-449 and PLC/PRF/5). 
EGFR and HER2 protein expression in HCC cells was determined using western blot 
analysis. The cytotoxicity of ZD 1839 on HCC cell growth was evaluated by 
3-(4,5-dimethylthiazol-2-yl)-2,5 -diphenyI tetrazolium bromide (MTT) assay and the 
effect of ZD 1839 in combination with ionizing radiation was assessed by clonogenic 
assay. The nucleotide sequence of EGFR and HER2 within tyrosine kinase (TK) 
domain was investigated using direct sequencing. The influence on cell cycle 
distribution by ZD 1839 was inspected by immunohistochemistry. 
All five HCC cell lines showed EGFR protein expression, among which 
SNU-449 possessed a relatively higher expression level than other HCC cell lines. 
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MTT assay revealed that treatment with ZD 1839 on HCC cells for 72 hr reduced cell 
growth in a dose-dependent manner. Sensitivity of SNU-423 and PLC/PRF/5 cells to 
ZD 1839 was higher than other three cell lines. No mutation was found within TK 
domains of EGFR (exons 18-21) and HER2 (exons 18-24) in any of the five cell 
lines. SNU-387 and SNU-423 contained silent substitutions at codon 819 and 787 in 
EGFR TK domain respectively. Pre-exposure and continuous exposure to ZD 1839 in 
combination with a single-dose ionizing radiation (0, 1，2, 4，and 6 Gy) showed no 
enhanced radiation response on HCC cells as compared with the controls. A notable 
increase (29%) in growth arrest at Go and early Gi phases of PLC/PRF/5 cells was 
observed upon exposure to ZD 1839, whereas other four cell lines demonstrated 2-5% 
incline at Go and early Gi phases. 
ZD 1839 can inhibit HCC cell growth. The higher sensitivity of SNU-423 and 
PLC/PRF/5 cells to ZD 1839 is not related to (i) EGFR protein expression, (ii) 
somatic mutation in TK domain of EGFR, (iii) HER2 protein expression and, (iv) 
somatic mutation in TK domain of HER2. An increase of tumor cells at Go and early 
Gi phases, which is known to be more resistant to ionizing radiation, after ZD 1839 
incubation may contribute to the lack of radiation sensitizing effect on PLC/PRF/5 
cell line. These results indicate ZD 1839 is unlikely to be used as a radiation 
sensitizer in HCC and future studies should focus on identifying factors contribute to 
- i i -
high sensitivity of SNU-423 and PLC/PRF/5 cells to ZD 1839 treatment. 
/ 























量的輻射線（0，1，2，4及6 Gy)處理後，結果顯示ZD 1839沒有增加肝細胞 
癌系的感輻射線度。另一方面，ZD1839能顯著地増加停滯在Go和早Gi生長階 
段的PLC/PRF/5癌細胞數量達29%，而在其餘的四個肝細胞癌系中，此增加只 
達 2 - 5 % � 
此項硏究顯示，ZD1839可以抑制肝細胞癌的生長�SNU-423及PLC/PRF/5 
細胞系對ZD 1839較高的敏感性並不涉及其(i) EGFR蛋白質表現度、（ii) EGFR 
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The incidence of hepatocellular carcinoma (HCC) has increased in prevalent 
regions including Asia and Africa (Pisani et al., 1993; Pisani et al., 1999; Parkin, 
2001; Parkin et al., 2001; Yang et al., 2005). Similar trend is observed in western 
countries such as United Kingdom and the United States (Taylor-Robinson et al., 
1997; Deuffic et al., 1998; El-Serag & Mason，1999). Surgery and liver 
transplantation play a crucial role in HCC treatment, but only about 30-40% of 
patients are eligible by the time of diagnosis (Taylor-Robinson et al, 1997; Tang, 
2001; Llovet et al., 2003). Most HCC patients are diagnosed at advanced stages 
when these radical treatment modalities are not possible. Chemotherapy or 
radiotherapy might be the alternative for unresectable HCC (Tang, 2001; Cahill & 
Braccia, 2004; Park et al., 2005). Nevertheless, long-term survival of patients 
remains poor when chemotherapy or radiotherapy is used as a single modality (Park 
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Introduction 
et al., 2005). Therefore, the use of novel agents directed at specific molecular 
elements to modulate cell growth and/or radiation response may offer an attractive 
approach for improving tumor control. 
Epidermal growth factor receptor (EGFR) represents a promising therapeutic 
target for cancer therapy since it serves as a major player in tumorigenesis and 
frequently associates with poor prognosis (Saloman et al., 1995; Woodbum, 1999; 
Nicholson et al., 2001). EGFR is a 170-kDa glycoprotein comprising with an 
extracellular ligand-binding domain, a transmembrane hydrophobic domain, and an 
intracellular tyrosine kinase (TK) domain (Medico & Comoglio，2000; Castillo et al., 
2004; Harari, 2004; Ranson & Wasdell, 2004). The chief contributor in activation of 
EGFR is the receptor ligand, which binds to the extracellular domain of the 
corresponding receptor. After dimerization of EGFR, activation of TK domain and 
autophosphorylation of the receptor are resulted, leading to activation of downstream 
signaling pathways that regulate cell proliferation and survival (Ullrich & 
Schiessinger, 1990; Woodbum, 1999; Medico & Comoglio，2000; Yarden & 
Sliwkowski, 2001; Jorissen et al., 2003). Current reports showed that blockade of 
EGFR signaling produced growth inhibition in various human cancer cell lines, such 
as mammary, colon, ovary and glioblastoma (Wollman et al., 1994; Bianco et al., 
- 2 -
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2002: Stea et al., 2003). Inhibition of EGFR signal transduction in mice bearing 
human head and neck (H&N) xenografts illustrated a significant transient tumor 
growth delay for > 30 days (Harari & Huang，2001). Increasing findings has recently 
demonstrated the relationship between EGFR signal transduction network and tumor 
resistance to radiation. In various murine carcinomas including ovarian, mammary 
and hepatocarcinoma, the level of EGFR protein expression in tumor cells was 
positively associated with tumor radioresistance in vivo (Akimoto et al., 1999). 
Disruption of EGFR signaling in a human H&N cancer cell line SQ20B resulted in 
sensitizing tumor cells to radiation, demonstrating EGFR interfered radiation 
response of tumor cells (Gupta et al, 2002)�This outcome was in agreement with 
study performed by Wollman et al. (1994)， exposure of EGFR to its ligands， 
epidermal growth factor (EGF) for example, before ionizing radiation gave an 
enhanced radioresistance on a human mammary carcinoma cell line MCF-7. 
Inhibition of EGFR, accordingly, represents a promising molecular target for 
suppressing tumor cell growth and improving antitumor effect of ionizing radiation. 
ZD 1839 is a low molecular weight synthetic anilinoquinazoline with the 
chemical name 4 - quinazolinamine, N - (3 -chloro-4-fluorophenyl) - 7 - methoxy - 6 
- ( 3 - (4-morpholin) propoxy). This anilinoquinazoline is an orally active EGFR 
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tyrosine kinase inhibitor (TKI). The drug competes with adenosine triphosphate 
(ATP) from binding to the intracellular TK domain of EGFR, in this manner 
blocking the EGFR signal transduction pathway (Frampton & Easthope，2004; 
Herbst et al., 2004; Ranson & Wasddl, 2004). Incubation with ZD 1839 in human 
cancer cell lines resulted in decreased EGFR phosphorylation, thus, confirmed the 
interference in EGFR signal transduction network by ZD 1839 (Gupta et al., 2002; 
Stea et al., 2003; Xu et al., 2003; Taira et al., 2006). The effects of ZD 1839 on 
inhibiting cell growth and enhancing radiation response of tumor cells have been 
demonstrated in vitro and in vivo. For instance, a dose-dependent inhibition of cell 
growth was obtained in human H&N cancer, and glioblastoma grown in vivo upon 
exposure to ZD1839 (Huang et al., 2002; Stea et al., 2003). ZD1839 treatment 
showed 40-80% growth inhibition against a range of human tumor xenografts, 
comprising prostate, lung, breast and mesothelioma (Sirotnak et al., 2000; She et al., 
2003). In addition, combination of ZD 1839 and radiation treatments led to 
synergistic reduction of clonogenic survival in various human cancer cell lines, 
including glioblastoma and vulvar squamous cells (Solomon et al., 2003; Stea et al., 
2003). Radiotherapy response of a human colorectal carcinoma LoVo was also 
enhanced by ZD 1839 treatment (Williams et al., 2002). Addition of ZD 1839 to 
radiation therapy for human carcinoma xenografts resulted in tumor growth delay 
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(Bianco et cd., 2002; Solomon et al, 2003). Inhibition of EGFR signaling might 
decrease the tumor growth rate and increase the radiation sensitivity of tumor cells. 
Two biologic factors may influence the effect of EGFR inhibition. Firstly, 
expression of other EGFR family members such as HER2, a preferred dimer partner 
of EGFR, might alter sensitivity of tumor cells to ZD 1839. The TK domain activities 
of these members might also be inhibited by ZD 1839 and lead to a great level of cell 
y 
death. Previous studies had described lung cancer cell lines overexpressing HER2 
showed a 2-fold higher sensitivity to ZD1839 than the very low expressing ones as 
measured by cell viability assay (Hirata et aL, 2005). Secondly, sensitivity to 
ZD1839 is related to mutations in TK domain of EGFR. This relationship is 
established by studies demonstrating dramatic response to ZD 1839 in patients with 
in-frame deletions and missense mutations in the TK domain of EGFR (Lynch et al, 
2004; Paez et al., 2004). Moreover，mutations within TK domain of HER2 were also 
detected but its effect on sensitivity to ZD 1839 remains unclear (Stephens et al., 
2004; Shigematsu et al., 2005). 
The achievement of radiosensitization effect by ZD 1839 remains controversial. 
Although ZD 1839 exhibited an enhanced radiation response on various tumor cells 
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(Bianco et aL, 2002; Huang et al., 2002; Williams et al‘, 2002; Solomon et al., 2003), 
several reports have suggested this effect is manipulated by multiple factors. One of 
these major factors is associated with the ability of ZD 1839 to suppress tumor cell 
proliferation. ZD 1839 can induce an increase of cell growth arrest at Gi phase and 
reduce the portion of cells in S phase (Huang et al., 2002). With reference to a study 
on the effect of X-rays on synchronously dividing cells, Gi phase has been 
ascertained to be more resistant to ionizing radiation than other phases (Hall, 2000), 
/ 
demonstrating the opportunity of reducing the cytotoxic effects by radiation on tumor 
cells. 
The present study aimed to investigate the cytotoxic and the radiosensitivity 
effect of ZD 1839 on HCC cell lines. Further examinations for mechanisms that 
plausibly interfered in the responses ofHCC cells to ZD 1839 and radiation would be 





2.1 Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide 
and the third leading cause of cancer death (Pisani et al., 1993; Pisani et al., 1999; 
Parkin, 2001; Parkin et al., 2001; Yang et al” 2005). Recently, the incidence of HCC 
has increased in western countries including France, United Kingdom and the United 
States (Taylor-Robinson et al., 1997; Deuffic et al., 1998; El-Serag & Mason，1999). 
There was an estimation of 564，000 new cases of HCC in 2000 (Parkin et al., 2001). 
Infection with hepatitis B and C virus, and ingestion of aflatoxin B1 
(AFB1 )-contaminated food are the major risk factors for HCC (Sun et al., 1999; 
Tang, 2001). 
Liver resection, transplantation and percutaneous treatments are the only 
curative treatments for HCC, but few patients are eligible at time of diagnosis 
- 7 -
Literature Review 
(Taylor-Robinson et al, 1997; Tang, 2001; Llovet et al, 2003), Resection is 
indicated for patients with one asymptomatic HCC and extremely well-preserved 
liver function (Llovet et al., 2002; Blum, 2005). The 5-year survival rate of patients 
with resected small HCC (< 5 cm) was 62.7% (Zhou et al., 2001). Survival rate 
dropped to 37.1% for patients with resected large HCC (> 5 cm) (Zhou et al., 2001). 
Liver transplantation is theoretically the optimal treatment strategy for HCC due to 
its dual function on curing the tumor and the underlying cirrhosis. The best 
candidates for such treatment are those possess one HCC < 5 cm or up to three 
nodules < 3 cm, who achieve 70% survival at 5 years (Blum，2005). Nevertheless, 
donor shortage limits the applicability of cadaveric liver transplantation (Llovet et al., 
2003). Percutaneous treatments, either chemically or thermally, are considered as 
effective for early unresectable HCC, in which patients with HCC < 5 cm can 
achieve a 5-year survival of around 50% (Llovet et al., 2003; Blum, 2005). 
Palliative treatments are applied among patients in advanced tumor stages. 
Although transcatheter arterial chemoembolisation is a widely used treatment for 
unresectable HCC, particularly for patients with multinodular HCC and acceptable 
liver function (Tang, 2001; Llovet et al., 2003), moderate side effects such as 
abdominal pain and fever are common (Bayraktar et al., 1996; Liu & Fan，1997). 
Chemotherapy or radiotherapy may convert an unresectable HCC to resectable in 
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only selective cases (Tang, 2001; Cahill & Braccia, 2004; Park et al., 2005), 
However, long-term survival of patients remains poor when chemotherapy or 
radiotherapy is used as a single modality. For instance, in a study of 59 patients with 
unresectable HCC, although 66.1% showed objective tumor response after treating 
with localized radiation, several of them possessed new intrahepatic metastasis and 
extrahepatic metastasis, and the 2-year overall survival rate upon the beginning of 
radiation was 27.4% (Park et al, 2005). Thus, the use of novel chemotherapy agents 
directed at specific molecular components to modify cell growth control and 
radiation response provides a new strategy for improving tumor control. 
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2.2 Epidermal Growth Factor Receptor 
Growth factor signaling pathways is a focus of research for novel antitumor 
agents. An important mediator of growth factor signaling pathways is the epidermal 
growth factor receptor (EGFR), one of the members of the EGFR family. EGFR is a 
170-kDa glycoprotein comprising with three functional domains: (i) an extracellular 
ligand-binding domain, (ii) a transmembrane hydrophobic domain, and (iii) an 
intracellular tyrosine kinase (TK) domain (Fig. 2.1a) (Medico & Comoglio, 2000; 
y 
Castillo et aL, 2004; Harari, 2004; Ranson & Wasdell，2004). 
2.2.1 Activation of Epidermal Growth Factor Receptor 
Several ligands have been shown to be capable of binding with EGFR, 
including epidermal growth factor (EGF), transforming growth factor (TGF)-a, 
amphiregulin, and heparin-binding EGF (Huang & Harari, 1999; Jones et al., 1999; 
Medico & Comoglio, 2000). Subsequent to ligand binding, EGFR undergoes 
dimerization, either forming homo- or hetero-dimeric complexes, which in turn leads 
to activation of TK domain (Fig. 2.1b-2.1c) (Medico & Comoglio, 2000). Following 
autophosphorylation of the receptor, recruitment and phosphorylation of intracellular 
substrates occurs while phosphotyrosine residues serve as docking sites for signal 
transducing proteins (Ullrich & Schiessinger, 1990; Medico & Comoglio, 2000) that 
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Fig. 2.1 Mechanisms of receptor activation. 
(a) EGFR is comprised with three functional domains: an extracellular 
ligand-binding domain, a transmembrane hydrophobic domain, and an 
intracellular TK domain, (h and c) Ligand binding of EGFR results in homo-
or hetero-dimerization of receptor members, which in turn leads to 
activation of TK domain. Following autophosphorylation of the receptor, 
recruitment and phosphorylation of intracellular substrates occurs. 
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eventually contributes to initiation of a cascade of intracellular signaling pathways 
mediating cell differentiation, growth, adhesion, migration and metastasis 
(Woodbum, 1999; Yarden & Sliwkowski, 2001; Jorissen et aL, 2003). 
2.2.2 Epidermal Growth Factor Receptor Signaling Pathways 
An important downstream route of EGFR is via mitogen-activated protein 
kinases (MAP-K) pathway (Fig. 2.2). Adaptor protein Grb2, the major participant in 
EGF-dependent Ras activation, is constitutively bound to the Ras exchange factor 
Sos (Yarden & Sliwkowski，2001; Jorissen et aL, 2003). Upon autophosphorylation 
of EGFR, the recruitment of SH2 domain of Grb2/Sos complex for the receptor 
assists the interaction of Ras with Sos (Jorissen et al., 2003). The Ras-bound 
guanosine diphosphate (GDP) becomes guanosine triphosphate (GTP) and stimulates 
Ras activation, hence resulting in activation of serine/threonine kinase Raf-1 (Yarden 
& Sliwkowski, 2001; Jorissen et al., 2003). Through a sequence of intermediate 
kinases such as MEK, MAP-K were phosphorylated and activated，which leads to 
catalysis of nuclear transcription factor phosphorylation responsible for mediating 
cell proliferation and survival (Yarden & Sliwkowski, 2001; Jorissen et aL, 2003). 
EGFR signaling also activates the phosphatidylinositol-3 kinases (PI3-K) 
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pathway (Fig. 2.3). Activation of PI3-K la, by binding with phosphorylated EGFR 
through the SH2 domain of p85 subunit, generates 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) targeting the serine/theronine kinase 
Akt (Jorissen et aL, 2003). After attaching to lipid, the complexes are translocated to 
the plasma membrane where they are phosphorylated and activated by kinases such 
as phosphoinositide-dependent kinase-1 (PDK-1)，and eventually results in 
regulation of cell proliferation and survival (Jorissen et al., 2003). In addition, 
activated Akt also phosphorylates proteins Bad and ribosomal S6 kinase (S6K) that 
are the major mediators of the antiapoptotic effects of EGFR activation (Yarden & 
Sliwkowski, 2001). 
2.2.3 Expression Level and Patient Survival 
EGFR, which is frequently associated with aggressive growth behavior 
(Saloman et al., 1995; Woodbum, 1999; Nicholson et al., 2001), overexpresses in a 
wide variety of tumors including head and neck (H&N), ovarian, cervical, bladder, 
oesophageal and liver (Saloman et aL, 1995; Nicholson et al., 2001; Ito et al, 2001). 
In a previous clinical study performed by Lodge and colleagues (2003), an 
association between EGFR cytoplasmic expression and poor survival was 
demonstrated in node positive breast cancer patients (n = 66). Similar finding was 
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Fig. 2.2 Mitogen-activated protein kinases (MAP-K) pathway: an important 
downstream route of EGFR. 
Upon autophosphorylation of EGFR, the recruitment of Grh2/Sos complex 
occurs. The Ras-bound GDP becomes GTP and stimulates Ras activation, 
resulting in activation of Raf-1. Through a series of intermediate kinases 
such as MEK, MAP-K were phosphorylated and activated, which leads to 
catalysis of nuclear transcription factor phosphorylation responsible for 
mediating cell proliferation and survival 
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Fig. 2.3 Phosphatidylinositol-3 kinase (PI3-K) pathway: an important downstream 
route of EGFR. 
Phosphorylated EGFR binds with the p85 suhunit of PI3-K la, in which 
PIP3 is generated. After activation of Akt, lipid complexes are translocated 
to the plasma membrane where they are phosphotylated, and eventually 
results in regulation of cell proliferation and survival In addition, activated 
Akt also phosphorylates proteins Bad and ribosomal S6K that are the major 
mediators of the antiapoptotic effects of EGFR activation. 
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noted in primary laryngeal squamous cell carcinoma. The 5-year survival for patients 
with EGFR-positive tumors was 25% as compared to 81% for patients with 
EGFR-negative tumors (P < 0.0001) (Maurizi et al., 1996). The 5-year relapse-free 
survival was 24% and 77% for patients with EGFR-positive and -negative tumors 
respectively (P < 0.01) (Maurizi et al., 1996). In a study of 84 patients with HCC, 53 
cases showed high EGFR expression level as compared to adjacent noncancerous 
hepatocytes, and EGFR expression was significantly correlated with the proliferating 
activity (p<0.0001), intrahepatic metastasis (p<0.05), and differentiation (p<0.05) 
(Ito et a/., 2001). 
2.2.4 Epidermal Growth Factor Receptor Activity and Tumor Cell Growth 
Inhibition of EGFR, either by monoclonal antibodies (mAb) or tyrosine kinase 
inhibitors (TKI), suppresses tumor cell growth in various human cancer cell lines. 
Exposure of several human cancer cell lines to EGFR TKI showed a dose-dependent 
inhibition of colony formation (Bianco et al., 2002; Stea et al., 2003). A growth 
inhibition effect was observed after EGFR TKI treatment in three human squamous 
cell carcinoma (SCC) cell lines derived from H&N patients (Huang et al, 2002). 
Similar result was obtained in a human breast cancer cell line MCF-7 upon 
incubation with mAb against EGFR (Wollman et al, 1994). Treatment of mice 
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bearing human GEO colon cancer or A549 lung adenocarcinoma xenografts with an 
EGFR inhibitor showed a significant inhibition in tumor growth as compared with 
the control (Bianco et al., 2000; Bianco et al., 2002). Moreover, in a phase II study of 
erlotinib, an EGFR TKI, in 34 patients with advanced HCC, the median overall 
survival time of patients was 13 months and progression of the disease was delayed, 
in which 32% of patients were progression-free for 24 weeks (Philip et al, 2005). 
Strategy of EGFR blockade is encouraged to be a treatment modality in HCC. 
2.2.5 Epidermal Growth Factor Receptor Activity and Radiation 
EGFR signal transduction network not only contributes to cell proliferation and 
survival, but also correlates with tumor resistance to radiation. Akimoto et al. (1999) 
reported that magnitude of EGFR expression was positively associated with tumor 
radioresistance and inversely correlated with radiation-induced apoptosis in various 
murine carcinomas, including squamous cell and hepatocarcinoma, suggesting 
tumors with high EGFR expression level would have lower sensitivity to radiation. 
Continuous stimulation of EGFR by its ligands EGF prior to ionizing radiation 
conferred an enhanced radioresistance on a human mammary carcinoma cell line 
MCF-7, in which an anti-EGFR mAb C225 can abrogate the ligand effect on 
radiation resistance (Wollman et al., 1994). Similarly, examination on a H&N cancer 
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cell line SQ20B, a highly radioresistant cell line, by inhibiting EGFR, Ras，and 
PI3-K with their corresponding inhibitors individually resulted in radiosensitization 
(Gupta et al., 2002). This finding demonstrated EGFR had contributed to radiation 
resistance by signaling to PI3-K through Ras (Gupta et al., 2002). EGFR, 
consequently, represents an attractive target for improving antitumor effect of 
ionizing radiation. 
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2.3 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, ZD 1839 
ZD 1839 [4- quinazolinamine, N - (3-chloro-4-fluorophenyl) -7 - methoxy — 6 -
(3- (4-morpholin) propoxy)] (Gefitinib, Iressa; AstraZeneca, Wilmington, DE), a low 
molecular weight synthetic anilinoquinazoline, is an orally active EGFR TKI. It 
competes with adenosine triphosphate (ATP) from binding to the intracellular TK 
domain of EGFR (Frampton & Easthope, 2004; Herbst et al., 2004; Ranson & 
Wasdell, 2004). Autophosphorylation of EGFR was inhibited, thereby blocking the 
y 
signal transduction pathway (Frampton & Easthope, 2004; Ranson & Wasdell，2004). 
ZD 1839 was approved as line treatment for patients with advanced 
non-small-cell lung cancer (NSCLC) in 33 countries including Japan and the United 
States (Blackledge & Averbuch, 2004; Harari, 2004; Paez et al., 2004; Giaccone, 
2005). A multi-centre phase II study demonstrated that ZD 1839 had clinically 
important antitumor activity with the symptom improvement rates of patients > 35%, 
the median overall survival times > 7.5 months and the 1-year survival rates > 29% 
(Fukuoka et al., 2003). Treatment with ZD 1839 in various human cancer cell lines 
showed a decline in EGFR phosphorylation, hence, confirmed the interference in 
EGFR signal transduction network by ZD 1839. In the presence of ZD 1839, EGFR 
phosphorylation of U251 cells, a human glioblastoma cell line, was dramatically 
reduced in a dose-dependent manner (Stea et al., 2003). Likewise, exposure to 
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ZD 1839 resulted in decreased phosphorylation level of EGFR in a human H&N 
cancer cell line (SQ20B), a esophageal cancer cell line (TE-3) and two colon 
cancer cell lines (LoVo, HT-29) (Gupta et al, 2002; Xu et al., 2003; Taira et al., 
2006). Solomon et al (2003) demonstrated that ZD 1839 inhibited not only EGFR 
phosphorylation, but also Akt and MAP-K activation, which are downstream targets 
of EGFR, in human SCC cell line A431. In a phase I study of ZD 1839 monotherapy 
in five selected solid tumor types, including NSCLC, H&N, ovarian, colorectal and 
prostate, the drug was shown to inhibit EGFR and MAP-K activation significantly 
during treatment (Baselga et al., 2002). ZD 1839 was confirmed to be capable of 
blocking the EGFR signal transduction pathway. 
2.3.1 Tumor Cell Growth Control Activities of ZD1839 
ZD 1839 can modulate cell growth of tumor cells both in vitro and in vivo. In 
addition to a dose-dependent inhibition of cellular proliferation in three SCC cell 
lines (Huang et al., 2002), ZD 1839 can inhibit tumor cell colony formation in a 
dose-dependent manner in glioblastoma, colon, ovarian, breast and NSCLC grown in 
vitro (Bianco et al., 2002; Stea et al” 2003). Administration of ZD 1839 at 
concentration 150 mg/kg, the drug exhibited 70-80% growth inhibition against 
human prostate cancer xenografts, and 50-55% growth inhibition against human lung 
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cancer xenograft (Sirotnak et al., 2000). Single treatment with ZD 1839 produced a 
modest inhibition of tumor growth in a range of human tumor xenografts, including 
s e e , breast, NSCLC and mesothelioma (Huang et al, 2002; She et al., 2003). 
2.3.2 Factors Affecting the Tumor Cell Growth Control Activities of ZD1839 
HER2 is one of the four members of the EGFR family with molecular size of 
185 kDa (Saloman et al., 1995). HER2 shares the common structural features with 
EGFR and has the high degree of sequence identity (83%) in the TK domain (Harari, 
2004), but there was no identifiable ligand binding (Yarden & Sliwkowski, 2001; 
Citri et al, 2003; Harari, 2004). Heterodimeric complex formation of HER2 with 
other members of EGFR family leads to HER2 activation (Goldman et al., 1990; 
Wada et al., 1990). HER2 is recruited as a preferred partner of EGFR (Kaninagaran 
et al., 1996; Tzahar et al., 1996; Lenferink et al., 1998) since activated heterodimers 
containing HER2 can be recycled causing enhanced signaling (Lenferink et al., 1998) 
and the rate of ligand dissociation from the cognate EGFR is decreased (Kaninagaran 
et al., 1996; Yarden & Sliwkowski, 2001), indicating cross communication between 
EGFR and HER2. ZD 1839 can inhibit HER2 phosphorylation with an IC50 10-fold 
greater than that against EGFR (Moulder et al, 2001). In a panel of ten breast and 
one ovarian cancer cell lines, HER2-overexpressing cells were more sensitive to 
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ZD 1839, with IC50 values 2- to 60-fold less than tumor cells without 
HER2-overexpression (Moasser et al., 2001). HER2 cDNA transfected lung cancer 
cell lines overexpressing HER2 showed a 2-fold higher sensitivity to ZD 1839 than 
the low expressing ones (Hirata et al., 2005). Treatment of HER2-overexpressing 
human breast cancer cell lines that coexpress EGFR with ZD 1839 resulted in 
considerable inhibition of HER2 phosphorylation (Moulder et al., 2001). Therefore， 
overexpression of HER2 seems to alter the sensitivity of tumor cells to ZD 1839. 
Another factor affecting the sensitivity of tumor cells to ZD 1839 is the presence 
of mutations in the TK domain sequence of EGFR gene (Table 2.1). Lung cancer 
patients with dramatic responses to ZD 1839 commonly have somatic mutations in 
the EGFR TK domain, including in-frame deletions of four amino acids 746 through 
750 within exon 19 removing leucine, arginine, glutamic acid and alanine, and 
missense mutations within exon 18 (G719C) and exon 21 (L858R and L861Q) 
(Lynch et al., 2004). On the contrary, treatment response is less common in wild type 
EGFR (Lynch et al., 2004). Biopsy samples of ZD 1839-responsive patients with lung 
adenocarcinoma, bronchioloalveolar carcinoma or large cell carcinoma revealed a 
15-bp in-frame deletion of five amino acids 722 through 726 within exon 19 (Amann 
et al, 2005). Among ZD 1839-responsive NSCLC patients, EGFR mutations were 
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Table 2.1 Examples of mutations within TK domain of EGFR. 
Exon Mutation site Effect of mutation Reference 
18 G719C Missense mutation: Lynch et al, 2004 
Glycine to cysteine 
18 G719S Missense mutation: Paez et al，2004 
Glycine to serine 
19 Codons 746 In-frame deletions: Lynch et a/., 2004 
through 750 Glutamic acid，leucine, arginine, and Paez et al., 2004 
alanine Kosaka et al., 2004 
19 Codons 751 In-frame deletions: Paez et al., 2004 
through 759 Threonine, serine, proline, lysine, 
alanine, asparagine, glutamic acid, 
isoleucine 
21 L858R Missense mutation: Lynch et a/., 2004 
Leucine to arginine Paez et al, 2004 
Kosaka et aL, 2004 
21 L861Q Missense mutation: Lynch et al., 2004 
Leucine to glutamine 
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frequently observed within exons 18 through 21 of TK domain (Paez et al., 2004). In 
Cos-7 cells transfected with constructs containing mutations within EGFR TK 
domain, its sensitivity to ZD 1839 was 6-fold higher as compared with the wild type 
(Lynch et al., 2004). Similarly, a human lung adenocarcinoma cell line H3255 
harboring L858R mutation demonstrated an extraordinary sensitivity to ZD 1839, 
roughly 100 times higher than the wild type (Paez et al., 2004). Administration of 
ZD 1839 to 293T cells holding a mutant EGFR showed a 4-fold increase in sensitivity 
y 
to TKI when compared with wild type (Amann et al., 2005). Accordingly，current 
studies proposed a relationship between sensitivity to ZD 1839 and EGFR mutations. 
Sordella et al (2004) demonstrated the mutant EGFRs phosphorylated two 
C-terminal sites that were not phosphorylated by wild type one, indicating mutant 
EGFRs transduced signals distinct from that mediated by wild type and led to notable 
responsiveness to ZD 1839. Moreover, provided that these mutations are clustered 
around ATP binding site of EGFR, Lynch et al. (2004) and Paez et al (2004) 
postulated EGFR mutations might cause structural alteration in TK domain and 
affect the specificity or interaction with both ATP and ZD 1839. Hence, the presence 
of mutations in EGFR TK domain is the main reason for sensitivity of tumor cells to 
ZD 1839. In-frame insertions in HER2 TK domain were reported in lung 
adenocarcinomas, and missense substitutions were found in glioblastoma, gastric and 
- 2 4 -
Literature Review 
ovarian primary cancers (Stephens et al, 2004). Shigematsu et al. (2005) also 
located in-frame insertions within exon 20 of HER2 TK sequence in lung 
adenocarcinoma primary tumors and cell line. Since EGFR and HER2 are both 
members of the EGFR family, and the EGFR mutations appear to be a major 
determinant of response to ZD 1839，therefore, HER2 mutations might also affect the 
sensitivity of tumor cells to ZD 1839. 
2.3.3 Radiosensitization Activities of ZD 1839 
The ability of ZD 1839 to alter radiation response of tumor cells has been 
examined in vitro and in wVo�Radiation response of human colorectal carcinoma and 
s e e cell lines of the H&N cancer was enhanced by ZD 1839 in both in vitro and in 
vivo models (Huang et al., 2002; Williams et al., 2002). Addition of ZD1839 to 
radiation treatment in human vulvar SCC resulted in statistically significant 
reduction of cell number when compared with radiation alone (Solomon et al., 2003). 
Single radiation treatment led to about 20% reduction of growth, whereas 
combination of ZD 1839 and radiation caused > 75% inhibition of clonogenic 
survival in a range of human cancer cell lines including colon, ovarian, breast and 
NSCLC (Bianco et al., 2002). Incubation with ZD1839 resulted in a 2.3- to 3.6-fold 
increase in radiosensitivity of human oral cancer cell lines HSC2 and HSC3 in in 
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vitro study (Shintani et al., 2003). A 3-fold reduction of tumor volume in human oral 
carcinoma xenografts was noted with radiosensitization by ZD 1839 treatment 
(Shintani et al., 2003). Similar finding was observed in human lung adenocarcinoma, 
colon cancer and mesothlioma xenografts when combination of ZD 1839 and 
radiation was used (Bianco et al., 2002; She et al., 2003). 
2.3.4 Factors Affecting the Radiosensitization Activities of ZD 1839 
The capacity of ZD 1839 to enhance radiosensitization effect of tumor cells 
remains controversial due to inhibition of EGFR signaling pathway with ZD 1839 
causes cell cycle arrest early in Gi phase. Regarding a study on the effect of X-rays 
on synchronously dividing cells, cells in Gi phase are known to be more resistant to 
ionizing radiation (Hall, 2000). After a 24-hr incubation with ZD 1839 in a human 
breast cancer cell line (BT-474), the proportion of tumor cells in Gi phase increased 
by 14% with a corresponding 11% decrease in S phase (Moulder et al., 2001). In 
ZD 1839-responsive lung cancer cell lines, ZD 1839 treatment caused an 
approximately 8% increase of cells in Gq/Gi phase (Hirata et al., 2005). ZD 1839 was 
also shown to increase the portion of tumor cells in Gq/Gi phase from 60.8% to 
91.8% in oral cancer cell lines (Shintani et al., 2003). Human SCC cell lines 
incubated with ZD 1839 arrested tumor cells at G! phase and decreased portion of 
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cells at S phase (Huang et aL, 2002). This observation was further supported by the 
effect of ZD 1839 on the expression of several key regulators of Gi to S phase 
progression. In vitro ZD 1839 treatment resulted in an increase of p27 protein 
expression which is known to inhibit cyclin-dependent kinase activity and decrease 
cyclin D1 expression (Moulder et al., 2001; Huang et al., 2002; Hirata et al., 2005). 
A phase I trial of ZD 1839 confirmed an increase of p27 expression in skin biopsies 
of patient receiving therapy (Baselga et al., 2002). Hence, arrest of tumor cells at Gi 
phase by ZD 1839 might influence the cytotoxic effects of ionizing radiation on 
tumor cells. 
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2.4 Study Objectives 
Taken together, the possibility of controlling tumor cell growth by ZD 1839 alone 
as well as combining with ionizing radiation has generated a vdde interest as an 
antitumor therapeutic approach. Due to limited available information about the effect 
of ZD1839 on growth and radiation response of HCC cells, the major objectives of 
the present study were: 
(i) to detect EGFR expression in various HCC cell lines (Hep3B, SNU-387, 
SNU-423, SNU-449 and PLC PRJF/5), • 
(ii) to determine, and analyze the effect of ZD1839 on HCC cell growth, 
(iii)to inspect, and analyze the effect of ZD 1839 pre-treatment and continuous 
treatment on radiosensitivity ofHCC cell lines. 
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Chapter 3 
Materials and Methods 
> 
3.1 ZD1839 
ZD 1839 was suppled by AstraZeneca (Cheshire, UK). ZD 1839 was dissolved in 
dimethyl sulfoxide (DMSO) at concentration 50 mM, and 10 |al aliquots were stored 
at -20°C. It was diluted in culture medium immediately prior to addition to cell lines. 
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3.2 Cell lines and Cell Culture 
Culture media and reagents used were purchased from Gibco，Carlsbad, CA, 
USA. 
Human lung adenocarcinoma cell lines NCI-H1650 and NCI-H1975 used for 
nucleotide sequence analysis; and human HCC cell lines SNU-387, SNU-423, and 
SNU-449 were maintained in RPMI 1640 supplemented with 10% fetal bovine 
serum (FBS), 50 units/ml penicillin, and 50 jj,g/ml streptomycin. 
Human epidermoid carcinoma cell line A431 used in immimoblot analysis; as 
well as human HCC cell lines Hep3B and PLC/PRF/5 were cultured in DMEM 
supplemented with 10% FBS, 50 units/ml penicillin, 50 |Lig/ml streptomycin, and 100 
pM non-essential amino acids. 
All cells were incubated in a 95% humidified incubator at 3TC with 5% CO2. 
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3.3 Immunoblot Analysis 
EGFR and HER2 protein expression in five HCC cell lines (Hep3B, SNU-387, 
SNU-423, SNU-449 and PLC/PRF/5) was determined using western blot analysis. 
3.3.1 Total Protein Extraction 
A monolayer of exponentially growing HCC cells were harvested by 
trypsinization and washed twice with phosphate buffered saline (PBS). After cell 
pellets were lysed in 2 volumes ice-cold lysis buffer [20 mM Tris (pH 8), 150 mM 
sodium chloride (NaCl), 5 mM ethylenediaminetetraacetic acid (EDTA), 0.2% 
bovine serum albumin (BSA), 1% Triton X-100, 1 |j,g/ml aprotinin, 1 mM 
phenylmethylsulfonylfluoride (PMSF), and 1 mM sodium vanadium oxide (Na3V04)] 
and homogenized using 25 G syringes (TERUMO, Toyko，Japan), the lysates were 
further incubated on ice for 40 min with low speed vortexing periodically. Cellular 
contents in the lysates were cleared by centrifugation at 13000 rpm for 15 min at 4�C 
(Centrifuge 5804R, Eppendorf, Hamburg, Germany). The supematants were 
collected and stored at -20°C until required. 
3.3.2 Protein Amount Determination 
The protein concentration of supematants was determined using � P r o t e i n 
Assay kit (Bio-Rad，Hercules, CA, USA). In brief, six dilutions of a protein standard 
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containing from 0.2 mg/ml to 1.5 mg/ml BSA and two dilutions (10-fold and 40-fold) 
of each sample were prepared in a 96-well flat-bottom plate (Nalge Nunc 
International, Rochester, New York, USA). In order to obtain the working reagent A', 
20 jil of reagent S was added to 1 ml of reagent A. Following the addition of 25 jil 
working reagent A’ into each well, 200 \il reagent B was added and mixed by gentle 
agitating. The contents were incubated at room temperature (RT) for 15 min prior to 
reading absorbances at 700 nm in a microplate reader (TECAN spectra, Tecan Group 
Ltd, Raleigh, NC, USA). Each experiment was performed in 2 replicate wells for 
each dilution. The amount of protein in each sample was determined from the 
standard curve plotting mean absorbance at 700 run against concentration of BSA by 
equation: 
protein concentration = (mean absorbance - constant) / slope of the curve 
3.3.3 Protein Separation 
Subsequent to the preparation of a 10% sodium dodecyl sulfate 
(SDS)-polyacrylamide gel [10% acrylamide mix, 375 mM Tris-base (pH 8.8)，0.1% 
SDS, 0.1% ammonium persulfate (APS), 4 \il NNN'N'-tetramethylethylenediamine 
(TEMED)], a 5% SDS-polyacrylamide gel [5% acrylamide mix, 125 mM Tris-base 
(pH 6.8), 0.1% SDS, 0.1% APS, 4 |il TEMED] was set on the top. One hundred 
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micrograms of protein extracts was mixed with equal volume of loading dye, and 
incubated at 95°C for 5 min. The mixtures and protein standard were 
electrophoretically stacked on the 5% gel at 60 V for 40 min, and separated on the 
10% gel at 100 V until reaching 1 cm above the bottom of the gel. 
3.3.4 Blotting 
After electrophoresis, the 10% gel and a piece of nitrocellulose membrane 
(Hybond-ECL, Amersham Biosciences, Buckinghamshire, England) were soaked in 
transfer buffer at RT for 15 min with shaking. The transfer components (Bio-Rad) 
with the gel and membrane were assembled as a sandwich: 
Cathode cassette plate I I 
Sponge I 1 
Filter paper [:::::::::::::::::::=::::二:::::::::::] 
Gel manmmKKKam 
Nitrocellulose membrane • • • • • • • • • • • 
Filter paper [:::::=::::::::::::::::::=::::] 
Sponge I 
Anode cassette plate I I 
After an ice pack and the cassette sandwich were put into the transfer tank filling 
with the transfer buffer, the tank was put into an ice bucket. Proteins were transferred 
to nitrocellulose membrane by running the blot at 100 V for 2 hr. 
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3.3.5 Antibody Labeling 
The membrane was removed from the transfer cassette and rinsed with 30 ml 
transfer buffer once. Non-specific binding sites on the membrane were blocked by 
immersing in 20 ml 5% skimmed milk in Tris-buffered saline-Tween (TBS-T) at RT 
for 60 min on a shaker. The membrane was briefly rinsed with 30 ml TBS-T before 
incubating with 15 ml diluted primary antibody (1:1000) in 1% skimmed milk in 
TBS-T specific for EGFR, and HER2 (BD Biosciences Pharmingen, San Jose, CA, 
0 
USA) at overnight with shaking. Following washing with 30 ml TBS-T at RT 
three times, each for 5 min, 15 ml diluted secondary antibody (1:1000) in 1% 
skimmed milk in TBS-T was applied at RT for 60 min on a shaker. The membrane 
was shook with 30 ml TBS-T three times and 30 ml Tris-buffered saline (TBS) twice, 
each for 5 min. In order to ensure that the amount of protein expression detected was 
not influenced by gel loading, membrane was reprobed with an anti- -actin primary 
antibody (Calbiochem, Darmstadt, Germany). 
3.3.6 Detection of Antibody Binding 
Specific bindings were visualized by chemiluminescance using ECL Western 
Blotting Detection Reagents (Amersham Biosciences) according to the 
manufacturer's manual. One millilitre detection solution mixture was added onto the 
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membrane. The membrane was wrapped and put in an X-ray film cassette after 1-min 
incubation at RT. Autoradiography films were developed varies from 10 sec to 5 min. 
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3.4 Cytotoxicity Assay 
The cytotoxicity of ZD 1839 on HCC cell growth was evaluated by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. MTT 
provides an indication of cellular proliferation status by measuring mitochondrial 
dehydrogenase activities within the cells. Exponentially growing HCC cells (4000 
cells/well) were seeded into a 96-well flat-bottom microtiter plate (Nalge Nunc 
International) and allowed to adhere for 24 hr in an incubator at 37°C with 5% CO2 
and 95% humidity. Medium was discarded from each well, and 200 jil medium 
containing various concentrations (0-100 |iM) of ZD 1839 was added. After 72-hr 
incubation, the medium containing ZD 1839 was removed and 50 |il MTT solution (1 
mg/ml) was added. The HCC cells were further incubated for 4 hr to allow MTT to 
form formazan crystals by reacting with metabolically active cells prior to the 
removal of MTT solution. The formazan crystals were solubilized in 100 jil DMSO 
solution. The absorbance of each well was measured in a microplate reader (TECAN 
spectra, Tecan Group Ltd) at 570 nm with a reference wavelength of 630 run. Each 
experiment was performed in 5 replicate wells for each drug concentration and was 
carried out three times independently. The percentage of cell viability was calculated 
by the equation: 
Average absorbance in the treatment group 
( ) X 100% 
Average absorbance in the control group 
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The dose-response curve was obtained by plotting mean percentage of cell viability 
against Log [ZD 1839] |iM using GraphPad Prism'^^ version 4.00 (GraphPad 
Software, San Diego, CA, USA). The IC50 value was defined as the concentration of 
ZD 1839 needed for a 50% reduction in the absorbance calculated based on the 
survival curves. 
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3.5 Nucleotide sequence analysis 
The TK domain nucleotide sequence of EGFR and HER2 was investigated by 
direct sequencing. 
3.5.1 Total RNA Extraction 
Total RNA was isolated from five HCC cell lines and two adenocarcinoma cell 
lines using TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) 
according to the protocol of the manufacturer. A monolayer of exponentially growing 
HCC cells were harvested by trypsinization and collected in 1.5 ml microcentrifuge 
tubes by centrifugation at 1000 rpm for 5 min. The cell pellets were lysed in 1 ml 
TRIzol Reagent by repetitive pipetting, followed by incubating the homogenized 
samples at RT for 5 min. Upon adding 200 [d chloroform, the tubes were secured and 
shook vigorously by hand for 15 sec. The samples were further incubated at RT for 3 
min before centrifuging at 12000 x g for 15 min at 4 � C (Centrifuge 5804R, 
Eppendorf). The upper aqueous layer containing total RNA of the samples was 
transferred to a fresh 1.5 ml microcentrifuge tubes and 500 |il isopropyl alcohol was 
added to the tubes. The content was mixed by inverting and incubated at RT for 10 
min. RNA pellets were collected by centrifugation at 12000 x g for 10 min at 4°C 
(Centrifuge 5804R, Eppendorf). After washing with 1 ml ice-cold 75% ethanol, the 
RNA pellets were dried at RT for 10 min. RNA pellets were dissolved in diethyl 
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pyrocarbonate (DEPC) treated-water and stored at -80°C until required. 
3.5.2 RNA Amount Determination 
One microlitre of total RNA from each sample was mixed with 49 [d TE buffer 
before transferring to a 50 \xl cuvette. The concentration and purity of total RNA 
was determined at A260 and A280 on a Beckman DU650 spectrophotometer 
(Beckman Coulter, Fullerton, CA, USA). 
3.5.3 Reverse Transcription - Polymerase Chain Reaction (RT-PCR) 
3.5.3.1 Reverse Transcription 
One microgram of total RNA from each sample was mixed with DEPC 
treated-water to obtain a volume of 3.8 jil. The diluted RNA samples were heated at 
90°C for 5 min and chilled on ice instantly. Reaction mixture [5 mM magnesium 
chloride (MgChX IX PGR buffer II, 4 mM dNTPs, 0.4 U/^il RNase inhibitor (Roche 
Applied Science, Mannheim, Germany), 2.5 U/jil Mulv reverse transcriptase (Roche 
Applied Science) and 2.5 [iM random hexamer (Applied Biosystems，Foster City, CA, 
USA)] was added to each diluted RNA sample to acquire a total volume of 20 |iL 
After 10-min incubation at RT，reverse transcription was performed in a GeneAmp 
PGR system 9700 (Applied Biosystems), with incubation at 42°C for 1 hr, followed 
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by 99°C for 5 min and final 4°C for 5 min. First-strand cDNA of each sample was 
kept at until required. 
3.5.3.2 High Fidelity Polymerase Chain Reaction 
Two microlitres of first-strand cDNA samples acted as template for PCR 
amplifications. Reaction mixture [IX PCR high fidelity buffer I, 0.4 jiM forward 
primer, 0.4 i^M reverse primer and 0.02 U/|il Taq high Fidelity] was added to the 
cDNA samples and incubated with thermal cycling conditions included 1 min at 
94°C; followed by 30 to 35 cycles of 30 sec at 94�C, 30 sec at 56°C, 1 min at 68°C; 
and 1 cycle of 7 min at 68°C in a GeneAmp PCR system 9700 (Applied Biosystems). 
The PCR products obtained were examined by electrophoresis on a 1.5% agarose gel 
with ethidium bromide in IX Tris-Borate-EDTA (TBE) buffer and visualized by a 
Gel Doc XR system (Bio-Rad). A housekeeping gene, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH)，was used as a standard to ensure successful reverse 
transcription of mRNA samples. The 4 exons (exons 18-21) within the TK domain of 
the EGFR gene were amplified with 2 oligonucleotide primers whereas the 7 exons 
(exons 18-24) of the entire HER2 TK domain were amplified with 2 pairs of 
oligonucleotide primers (Table 3.1). 
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Table 3.1 Sequences of primers used in high fidelity PCR. 
Target gene Primer Sequence (5' to 3，） 
GAPDH Forward ATCTCTGCCCCCTCTGCTGA 
/ 
Reverse GATGACCTTGCCCACAGCCT 
EGFR (exons 18-21) Forward ACCAAGCTCTCTTGAGGATC 
Reverse AAATTGATTCCAATGCCATCC 
HER2 (exons 18-20) Forward CTTTGGGATCCTCATCAAGC 
Reverse GACATGGTTGGGACTCTTGA 
HER2 (exons 21 -24) Forward CTTAGACCATGTCCGGGAAA 
Reverse GTACCAGATACTCCTCAGCA 
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3.5.4 Purification of PGR Product 
Two microlitres PGR product of mRNA samples using primers of EGFR and 
HER2 respectively were incubated with 2U of exonuclease I (New England Biolabs, 
Ipswich, MA, USA) and lU of shrimp alkaline phosphatase (Roche Applied Science) 
in a volume of 6.1 at 37°C for 1 hr, followed by 72°C for 15 min. 
3.5.5 Cycle Sequencing Reaction 
The purified PGR products were subjected to cycle sequencing reaction using 
BigDye Terminator kit v3.1 (Applied Biosystems). All reactions were carried out in 
10 pi volume containing 0.16 \xM forward or reverse primer of target gene, 2 j^ l 
BigDye v3.1 solution and 3 i^l purified PCR product. Conditions for the reaction 
were 30 cycles at 96°C for 20 sec, 50°C for 15 sec and 60°C for 2 min, followed by 
28°C for 2 sec and a 4°C soak. 
3.5.6 DNA Precipitation and Sequencing 
The content in each PCR tube was then transferred to clean 1.5 ml 
microcentrifuge tubes containing 1 |il of 3 M sodium acetate and 25 jj,l of 95% 
ethanoL Upon 30 min incubation, all microcentrifuge tubes were centrifuged at 
13000 rpm for 15 min. The supernatant was discarded and the pellets were washed 
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once with 125 |il of 70% ethanol. Centrifugation was performed at 13000 rpm for 5 
min prior to air-drying of the pellets for 15 min. Twelve microlitres Hi-Di formamide 
solution was added to the dried pellets for 5-min denaturation. The sequencing 
fragments were electrophoresed on the ABI Prism 3100 DNA analyzer (Applied 
Biosystems). Both forward and reverse sequences were analyzed by ClustalW with 
the EGFR and HER2 reference sequences from National Center for Biotechnology 
Information (EGFR: accession number NM005228, HER2: accession number 
NM004448). All sequence variants were reamplified and resequenced using the same 
experimental conditions. 
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3.6 Clonogenic Assay: 
The effect of ZD 1839 in combination with ionizing radiation was assessed by 
clonogenic assay. Exponentially growing HCC cells were seeded in twenty 25-cm^ 
tissue culture flasks (Nalge Nunc International) and allowed attaching for 24 hr. After 
removing the medium, the flasks were divided into four groups, and each group of 
HCC cells were treated with 5 ml medium containing 0, 1，5 and 10 i^M ZD 1839 
correspondingly for 72 hr in an incubator at 37�C with 5% CO2 and 95% humidity. 
/ 
At the end of the 72-hr incubation, a single fraction of superficial X-irradiation (100 
KVp / 8 mA / HVL2.35 mmAl) at graded doses 0，1，2, 4 and 6 Gy respectively was 
applied to corresponding flask in each group. HCC cells were immediately 
trypsinized, counted and replated into 6-well plates (Nalge Nunc International) in 
triplicate wells at cell density 200 - 1 x 10^  cells/well, depending on individual cell 
lines and treatment groups. In the first series of assay, the HCC cells were maintained 
in 3 ml medium free of ZD 1839 for 10 - 16 days with medium change on Day 11 
and Day 14 until colonies formed (Fig. 3.1a). Following incubation interval, colonies 
were stained with 1 ml of 1% crystal violet in 70% ethanol for 15 min. The 6-well 
plates were then washed with slow running tap water and colonies consisting of 50 
cells or more were scored. In the second series of assay, ZD1839-treated 
exponentially growing HCC cells were irradiated and replated for clonogenic 
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survival in medium containing the corresponding concentration of ZD 1839 prior to 
staining (Fig. 3.1b). The experiment was repeated separately using 3 replicate wells 
for each concentration and radiation dose. Plating efficiency (PE) of a HCC cell line 
was calculated by the equation: 
Average number of colonies formed 
( ) X 100% 
Average number of cells replated 
Survival fraction (S) of the radiation-treated group was evaluated by: 
Average number of colonies formed in treatment group 
( / P E of the control) x 100% 
Average number of cells replated in treatment group 
Survival fractions in ZD 1839- and radiation-treated groups were further normalized 
by their own drug control groups using the equation: 
S of the ZD 1839- and radiation-treated group 
( )X 100% 
S of the ZD1839-treated group 
A survival curve of each HCC cell line with a particular concentration of ZD 1839 
treatment was drawn by plotting the survival fraction of HCC cells against dose of 
superficial X-irradiation. 
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Day 0 1 3 10-16 
> ^ > < > < > k 
HCC cells X-irradiation exposure and, the Colony staining 
seeding end of ZD 183 9 pre-treatment 
Beginning of ZD 183 9 
pre-treatment 
(a) 
Day 0 1 3 10-16 
> V I < > > k 
HCC cells X-irradiation Exposure Colony staining, and the end of 
seeding ZD 1839 continuous treatment 
Beginning of ZD 1839 
continuous treatment 
(b) 
Fig. 3.1 Time schedule of clonogenic assay. 
(a) In the first series of assay, the ZD1839-treated HCC cells were irradiated, 
replated, and maintained in medium free of ZD1839 during colony forming 
period, (b) In the second series of assay, the ZD1839-treated HCC cells were 
irradiated, replated, and maintained in medium containing the 
corresponding concentration of ZD1829 during colony forming period. 
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3.7 Immunohistochemical Analysis 
The effect of ZD 1839 on cell cycle distribution in the Go and early Gi phases of 
HCC cells was examined by immunohistochemistry. Exponentially growing HCC 
cells were seeded in 100-mm tissue culture plates. Following 24-hr adhering, the 
medium was removed and the HCC cells were treated with 10 ml medium containing 
0 i^ M or 10 |iM ZD 1839 correspondingly for 72 hr in an incubator at 37°C with 5 % 
CO2 and 95% humidity. At the end of the 72 hr incubation, the cells were harvested 
by trypsinization, washed by PBS and collected in 15 ml centrifuge tubes by 
centrifugation at 1000 rpm for 5 min. Fixation for the HCC cells was carried out 
using 15 ml 7.5% buffered formalin at RT overnight. Agar (2%) was melted inside a 
metal container in boiling water and maintained at 70°C�After fixation, cell pellets 
were obtained by centrifugation at 1560 x g for 10 minutes and supernatant was 
discarded thoroughly. The cell pellets were mixed with 500 jiil of 2 % agar and 
incubated on ice for 10 min. The hardened agar was dislodged from the bottom of the 
tube with a wooden applicator. After cutting into small pieces, the cut agar was put 
inside the cassette for processing. Four micrometre sections were cut and mounted on 
silane-coated slides for antigen retrieval on an automatic Bond-max immunostainer 
(Vision BioSystems, Mount Waverley, Australia) using Bond Epitope Retrieval 
Solution 2 at 100°C for 25 min. Sections were incubated with 1:200 dilution of rabbit 
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monoclonal anti-Ki-67 antibody (Neomarkers, Fremont, USA) at RT for 25 minutes, 
followed by post primary antibody solution at RT for 8 min to enhance penetration of 
the subsequent polymer reagent.. The Bond™ polymer high contrast with 
counterstain detection kit (Vision BioSystems) was used to detect the primary 
antibody at RT according to manufacturer's instructions. In brief, after washing, 
sections were incubated with a poly-horseradish peroxidase anti-mouse/rabbit IgG 
reagent for 8 min. Substrate chromogen 3,3' -diaminobenzidine was then applied for 
y 
another 8 min to visualize the complex in brown colour, and hematoxylin 
coimterstaining was performed for 4 min. The proliferation marker was evaluated as 
present or absent. In order to classify the staining as present, retained staining in both 
nuclei and nucleolus was considered as positive. Only nucleolus staining was 
diagnosed as negative. The stained sections were evaluated in at least four fields 
(more than 1250 HCC cells) under light microscopy at a magnification of 400X. 
Slides were evaluated by two investigators (E.C. and D.Y.) independently. An 
agreement was achieved for each slide, and for the slides with great discrepancy, 
those sessions were reevaluated. 




4.1 Immunoblot Analysis 
EGFR and HER2 protein expression was assessed by western blot using 
anti-EGFR and anti-HER2 antibodies respectively. 
Protein concentrations of the five HCC cell lines were ranged from 6.30 mg/ml 
in Hep3B cells to 13.92 mg/ml in PLC/PRF/5 cells (Table 4.1). After separating 100 
|ig extracted protein of each HCC cell line on a 10% SDS-polyacrylamide gel, the 
protein was blotted onto a nitrocellulose membrane and probed with antibodies 
specific to EGFR and HER2. A 170-kDa EGFR protein was detected in Hep3B, 
SNU-387, SNU-423, SNU-449 and PLC/PRF/5 cell lines with comparable finding to 
the control cell line A431 (Fig. 4.1). SNU-449 possessed the highest expression level, 
whereas SNU-387 held the lowest expression level among the five cell lines. A 
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positive reactivity at bands that corresponded to the 185-kDa HER2 protein was 
identified in the five HCC cell lines, in which Hep3B contained the highest 
expression level and SNU-387 contained the lowest expression level among all cell 
lines tested (Fig 4.1). 
The purpose of the positive control is to serve as proof that the experiment can 
produce a positive result. In western blotting analysis, the positive control cell line 
/ 
A431 showed an expression of the targeted proteins, indicating that this protocol was 
capable of producing a positive result. On the other hand, a negative control serves as 
proof that a given protocol is able to give baseline results. The major purpose of 
western blotting analysis was to detect the expression of EGFR and HER2 proteins in 
HCC cells. The precise quantity of such proteins was beyond the aim of this study. 
Hence, a negative control for this experiment might not be essential. 
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Table 4.1 Protein concentration in whole cell extract of five HCC cell lines. 
# 社社 
HCC cell Dilution Absorbance at 700 nm Mean Absorbance Concentration of 
line factor Well 1 Well 2 at 700 nm protein (mg/ml) 
Hep3B 10 0.214 0.199 0.167 6.30 
SNU-387 10 0.280 0.255 0.268 9.79 
SNU-423 10 0.226 0.236 0.231 7.70 
SNU-449 10 0.252 0.234 0.243 8.39 
PLC/PRF/5 10 0.349 0.330 0.340 13.92 
The protein concentration was determined using ^c Protein Assay kit by reading 
absorbance at 700 nm. A monolayer of exponentially growing HCC cells were 
harvested by trypsinization and lysed in 2 volumes ice-cold lysis buffer. Two dilutions 
(10-fold and 40-fold) of each sample were prepared in a 96-well flat-bottom plate‘ 
Each experiment was performed in 2 replicate wells for each dilation� 
杜Only the absorbances of the 10-fold dilution felt within the absorbance range of the 
standard curve and were used to determine the extracted protein concentration of 
each HCC cell line. 
nn 
The protein concentration in each sample was determined from the standard curve 
of BSA concentration by equation: 
protein concentration = (mean absorbance-constant) / slope of the curve 
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鶴 一 m m — 一 HER2 
- 鮮P-actin 
Fig. 4.1 EGFR and HER2 protein expression in five HCC cell lines. 
EGFR and HER2 protein expression in HCC cells was determined by 
western blot. A hundred micrograms of cell lysates were electrophoretically 
separated on 10% SDS-polyacrylamide gels and blotted onto nitrocellulose 
membrane. Immunoblotted with anti-EGFR or anti-HER2 antibodies to 
demonstrate protein expression. 
社A human vulvar squamous cell carcinoma served as a positive control 
•Immunobht to P-actin was shown as loading controls. 
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4.2 Cytotoxicity Assay 
We investigated the growth inhibitory effect of ZD 1839 on human HCC cell 
lines by MTT assay. 
4.2.1 Effect of ZD 1839 on cell morphology 
The morphology of HCC cells was investigated under a lOOX microscope upon 
72-hr incubation with or without ZD 1839 respectively. After HCC cells treated with 
10 |jM ZD 1839，especially PLC/PRF/5, the cells showed a spindle-shape when 
/ 
compared with the non-treated cells (Fig. 4.2-4.3). This might be related to the 
growth inhibitory effect of ZD1839. A moderate proportion of ZD1839-treated HCC 
cells died and detached from the substratum. Under a low cell density condition, the 
remaining dying cells lost surface contact from their neighbors, in which microscopic 
change in cytoskeleton might occur. 
4.2.2 Effect of ZD 1839 on cell growth 
Exposure of exponentially growing SNU-423, SNU-449 and PLC/PRF/5 cells 
to >1 jiM ZD 1839 for 72 hr resulted in, generally, a dose-dependent growth 
inhibition (Fig. 4.4). On the other hand, 72-hr incubation with >10 |iM ZD 1839 was 
required to cause a dose-dependent growth inhibition effect in Hep3B and SNU-387 
cells (Fig. 4.5). The IC50 values of ZD 1839 against HCC cells ranged from 7 [iM to 
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28 |iM and they were apparently 2-fold lower in SNU-423 and PLC/PRF/5 cell lines 
(Fig. 4.6). 
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Fig. 4.2 Morphology of (a) Hep3B, (b) SNU-387, and (c) SNU-423 cell lines. 
At the end of the 72-hr incubation, HCC cells treated with 0 fiM (left) or 10 
juM (right) of ZD1839 were investigated under a 1OOX microscope. 
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Fig. 4.3 Morphology of (a) SNU-449 and (b) PLC/PRF/5 cell lines. 
At the end of the 72'hr incubation, HCC cells treated with 0 juM (left) or 10 
juM (right) of ZD1839 were investigated under a 1OOX microscope. 
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Fig. 4.4 Dose-response curves of (a) SNU-423, (b) SNU-449, and (c) PLC/PRF/5 
cell lines after 72 hr incubation of ZD 1839. 
The cytotoxicity of ZD1839 on HCC cell growth was evaluated by MTT 
assay. Exponentially growing HCC cells were incubated with various 
concentrations (0-100 juM) of ZD1839 for 72 hr. The results were expressed 
in mean absorbance 570 nm 土 S.D. with a reference wavelength of630 nm. 
Each experiment was performed in 5 replicate wells for each drug 
concentration and was carried out three times independently. 
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Fig. 4.5 Dose-response curves of (a) Hep3B and (b) SNU-387 cell lines after 72 hr 
incubation of ZD 1839. 
The cytotoxicity of ZD1839 on HCC cell growth was evaluated by MTT 
assay. Exponentially growing HCC cells were incubated with various 
concentrations (0-100 juM) of ZD1839 for 72 hr. The results were expressed 
in mean absorbance 570 nm 土 S.D. with a reference wavelength of 630 nm. 
Each experiment was performed in 5 replicate wells for each drug 
concentration and was carried out three times independently. 
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# Cell line IC50 (^M) 
Hep3B 21.080 ±2.083 
SNU-387 28.197 ±2.993 
SNU-423 10.688 土 0.799 
SNU-449 14.007 士 0.724 
PLC/PRF/5 7.002 士 0.959 
35 -
30 - ] 
_ 
- • • 
I I I I i 
HepSB SNU-387 SNU-423 SNU-449 PLC/PRF/5 
HCC cell lines 
Fig. 4.6 Concentration of ZD 1839 inhibiting HCC cell growth by 50% after 72 hr 
incubation. 
IC50 value was defined as the concentration of ZD1839 inhibiting HCC cell 
growth by 50% based on the dose-response curve. Each value was the mean 
concentration 土 S.D. of 3 independent experiments. 
Ji 
Table indicates IC^q values of ZD1839 against five HCC cell lines after 72 
hr incubation. 
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4.3 Nucleotide Sequence Analysis 
Mutation within the TK domains of EGFR and HER2 was screened by direct 
sequencing. 
4.3.1 RNA Concentration of HCC cells 
After extracting RNA from five HCC cell lines and two lung adenocarcinoma 
cell lines using TRIzol Reagent (Invitrogen Life Technologies, Carlsbad, CA，USA) 
according to the protocol of the manufacturer, the concentration and purity of total 
RNA was determined at A260 and A280 on a Beckman DU650 spectrophotometer 
(Beckman Coulter, Fullerton, CA, USA) (Table 4.2). 
4.3.2 Sequencing of TK domain within EGFR 
None of the five HCC cell lines had mutation in the TK domain of EGFR gene. 
Nonetheless, two cell lines contained silent substitutions. SNU-387 cells possessed 
the substitution at codon 819，which changed nucleotides GTG to GTA (Fig. 4.7a); 
whereas SNU-423 cells confirmed the substitution within codon 787 that changed 
nucleotides CAG to CAA (Fig. 4.7b). The NCI-H1650 and NCI-H1975 cell lines, 
human lung adenocarcinoma cell lines containing in-frame deletions within codon 
746 through codon 750 (DelE746A750) and missense mutation at codon 858 (L858R) 
in the TK domain of EGFR respectively, served as positive controls (Fig. 4.8). 
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4.3.3 Sequencing of TK domain within HER2 
Likewise, no sequence variations were identified in HER2 TK domain of all 
five HCC cell lines. 
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Table 4.2 RNA concentration of five HCC cell lines. 
Cell line NetAbsat NetAbsat 260.0/280.0 Dilution RNA concentration 
260.0 nm 280.0 run factor (iig/|il) 
Hep3B 0.4805 0.2413 1.9913 50 0.9610 
SNU-387 0.3286 0.1921 1.7103 50 0.6572 
SNU-423 0.4054 0.2048 1.9800 50 0.8109 
SNU-449 0.8185 0.3975 2.0594 50 1.6370 
PLC/PRF/5 1.8219 0.8906 2.0458 50 3.6438 
NCI-H1650 0.3810 0.1959 1.9451 50 0.7620 
NCI-H1975 0.7189 0.3563 2.0178 50 1.4378 
Concentration of total extracted RNA was determined at A260 and A280 on a 
spectrophotometer. Exponentially growing tumor cells were harvested by 
trypsinization and lysed in 1 ml TRIzol Reagent according to the protocol of the 
manufacturer. A 50-fold dilution of each sample was prepared in TE buffer. 
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Fig. 4.7 Silent substitutions within the TK domain of EGFR gene in (a) SNU-387 
cells at codon 819, and (b) SNU-423 cells at codon 787. 
Sequence variations within EGFR TK domain of HCC cells were detected 
by direct sequencing. One microgram of total RNA from each sample was 
subjected to RT-PCR. After purification, cDNA was cycle sequenced and 
sequencing fragments were electrophoresed. All sequence variants were 
reamplified and resequenced using the same experimental conditions. 
Tracing in sense direction of electopherograms were shown. The wild-type 
EGFR TK domain nucleotide sequence was shown on top. 
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Fig. 4.8 Mutations within the TK domain of EGFR gene in (a) NCI-H1650 cells 
(DelE746A750), and (b) NCI-H1975 cells (L858R). 
Sequence variations within EGFR TK domain of tumor cells were detected 
by direct sequencing. One microgram of total RNA from each sample was 
subjected to RT-PCR. After purification, cDNA was cycle sequenced and 
sequencing fragments were electrophoresed. All sequence variants were 
reamplified and resequenced using the same experimental conditions. 
Tracing in sense direction of electopherograms were shown. The wild-type 
EGFR TK domain nucleotide sequence was shown on top. 
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4.4 Clonogenic Assay 
In order to examine whether ZD 1839 could influence the sensitivity of HCC 
cells to ionizing radiation, experiments were conducted to evaluate the effect of 
ZD1839 on clonogenic survival. 
4.4.1 Effects of ZD 1839 pre-treatment on radiation response 
In the first series of experiment, HCC cells were incubated with ZD 1839 before 
and during ionizing radiation. After trypsinization, the HCC cells were replated into 
/ 
6-well plates containing medium free of ZD 1839 prior to staining. ZD 1839 
pre-treatment of HCC cells caused no apparent reduction in colony formation when 
compared with the control group, suggesting no obvious radiosensitization effect was 
obtained in HCC cells after exposure to ZD 1839 (Fig. 4.9-4.13). Increasing dosages 
of ZD 1839 failed to increase cell death when receiving the same ionizing radiation 
dosage. 
4.4.2 Effects of ZD 1839 continuous treatment on radiation response 
In the second series of experiment, clonogenic survival assay of HCC cells was 
carried out after ionizing radiation by replating cells in medium containing ZD 1839. 
Following incubation interval, colonies were stained with 1% crystal violet in 70% 
ethanol. Similarly, no reduction in cell survival was occurred in all HCC cells when 
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compared to control group without ZD 1839 treatment (Fig. 4.14-4.18). There was no 
enhancement of radiation response by continuous incubation of ZD 1839 in HCC 
cells. 
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Fig. 4.9 Effect of ZD 1839 pre-treatment on radiation response of Hep3B cell line. 
Exponentially growing HepSB cells were treated with ZDI839 (0，1, 5 and 
10 JLIM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0，1，2, 4 and 6 Gy) to corresponding flask in 
each group. HepSB cells were immediately trypsinized, counted and replated 
with medium free of ZD1839. Following 14-day incubation interval, colonies 
were stained with 1% crystal violet. Only colonies formed with more than 50 
cells were scored. Data in ZD1839/radiation treatment group were 
normalised by respective ZD1839 control, and were averaged from triplicate 
wells and duplicated experiments 士 S.E. 
- 6 7 -
Results 
10.000 _^XRTonly 
— ^ M ZD1839 + XRT 
— A — Z D 1 8 3 9 + XRT 
- ^ 1 0 ^M ZD1839 + XRT 






0.000 ‘ ‘ ‘ ‘ ‘ ‘ ‘ 
0 1 2 3 4 5 6 7 
XRT Dose (Gy) 
Fig. 4.10 Effect of ZD 1839 pre-treatment on radiation response of SNU-387 cell line. 
Exponentially growing SNU-387 cells were treated with ZD1839 (0，1, 5 
and 10 JLIM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0’ 1, 2, 4 and 6 Gy) to corresponding flask 
in each group. SNU-387 cells were immediately trypsinized, counted and 
reflated with medium free of ZD1839. Following 16-day incubation 
interval, colonies were stained with 1% crystal violet. Only colonies formed 
with more than 50 cells were scored. Data in ZDl839/radiation treatment 
group were normalised by respective ZD1839 control, and were averaged 
from triplicate wells and duplicated experiments 士 S.E. 
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Fig. 4.11 Effect of ZD 1839 pre-treatment on radiation response of SNU-423 cell line. 
Exponentially growing SNU-423 cells were treated with ZD1839 (0, 1，5 
and 10 juM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0, 1’ 2，4 and 6 Gy) to corresponding flask 
in each group. SNU-423 cells were immediately trypsinized, counted and 
replated with medium free of ZD1839. Following 14-day incubation 
interval, colonies were stained with 1% crystal violet. Only colonies formed 
with more than 50 cells were scored. Data in ZD1839/radiation treatment 
group were normalised by respective ZD1839 control, and were averaged 
from triplicate wells and duplicated experiments 士 S.E. 
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Fig. 4.12 Effect of ZD 1839 pre-treatment on radiation response of SNU-449 cell line. 
Exponentially growing SNU-449 cells were treated with ZD1839 (0, 1, 5 
and 10 /uM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0，1, 2, 4 and 6 Gy) to corresponding flask 
in each group. SNU-449 cells were immediately trypsinized, counted and 
replated with medium free of ZD1839. Following 10-day incubation 
interval, colonies were stained with 1% crystal violet. Only colonies formed 
with more than 50 cells were scored. Data in ZD1839/radiation treatment 
group were normalised by respective ZD1839 control, and were averaged 
from triplicate wells and duplicated experiments 士 S.E. 
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Fig. 4.13 Effect of ZD 1839 pre-treatment on radiation response of PLC/PRF/5 cells. 
Exponentially growing PLC/PRF/5 cells were treated with ZD1839 (0, 1，5 
and 10 JLIM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0’ 1, 2, 4 and 6 Gy) to corresponding flask 
in each group. PLC/PRF/5 cells were immediately trypsinized, counted and 
replated with medium free of ZD1839. Following 10-day incubation 
interval, colonies were stained with 1% crystal violet. Only colonies 
formed with more than 50 cells were scored. Data in ZD1839/radiation 
treatment group were normalised by respective ZD1839 control, and were 
averaged from triplicate wells and duplicated experiments 士 S.E. 
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Fig. 4.14 Effect of ZD 1839 continuous treatment on radiation response of HepSB 
cell line. 
Exponentially growing HepSB cells were treated with ZD1839 (0, 1’ 5 and 
10 jjM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0’ 1, 2, 4 and 6 Gy) to corresponding flask 
in each group. HepSB cells were immediately trypsinized, counted and 
reflated with medium containing ZD1839. Following 14-day incubation 
interval, colonies were stained with 1% crystal violet. Only colonies 
formed with more than 50 cells were scored. Data in ZD1839/radiation 
treatment group were normalised by respective ZD1839 control, and were 
averaged from triplicate wells and duplicated experiments ± S.E. 
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Fig. 4.15 Effect of ZD 1839 continuous treatment on radiation response of SNU-387 
cell line. 
Exponentially growing SNU-387 cells were treated with ZD1839 (0，1, 5 
and 10 juM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0’ 1, 2, 4 and 6 Gy) to corresponding flask 
in each group. SNU-387 cells were immediately trypsinized, counted and 
replated with medium containing ZD1839. Following 16-day incubation 
interval, colonies were stained with 1% crystal violet. Only colonies formed 
with more than 50 cells were scored. Data in ZD1839/radiation treatment 
group were normalised by respective ZD1839 control, and were averaged 
from triplicate wells and duplicated experiments 士 S.E. 
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Fig. 4.16 Effect of ZDl 839 continuous treatment on radiation response of SNU-423 
cell line. 
Exponentially growing SNU-423 cells were treated with ZD1839 (0’ 1, 5 
and 10 JJM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0’ 1’ 2, 4 and 6 Gy) to corresponding flask 
in each group. SNU-423 cells were immediately trypsinized, counted and 
reflated with medium containing ZD1839. Following 14-day incubation 
interval, colonies were stained with 1% crystal violet. Only colonies formed 
with more than 50 cells were scored. Data in ZDl839/radiation treatment 
group were normalised by respective ZD1839 control, and were averaged 
from triplicate wells and duplicated experiments 士 S.E. 
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Fig. 4.17 Effect of ZD 1839 continuous treatment on radiation response of SNU-449 
cell line. 
Exponentially growing SNU-449 cells were treated with ZD1839 (0, 1, 5 
and 10 juM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0，1’ 2’ 4 and 6 Gy) to corresponding flask 
in each group. SNU-449 cells were immediately trypsinized, counted and 
replated with medium containing ZD1839. Following 10-day incubation 
interval, colonies were stained with 1% crystal violet. Only colonies 
formed with more than 50 cells were scored. Data in ZD1839/radiation 
treatment group were normalised by respective ZD1839 control, and were 
averaged from triplicate wells and duplicated experiments 士 S.E. 
- 7 5 -
Results 
10.000� -^XRTonly 
- i H - 1 ^M ZD1839 + XRT 
—A—5|iM ZD1839 + XRT 
-^<—10 ^M ZD1839 + XRT 
1 � � � 




0.000 ‘ 1 1 ‘ 1 ‘ 1 
0 1 2 3 4 5 6 7 
XRT Dose (Gy) 
Fig. 4.18 Effect of ZD 1839 continuous treatment on radiation response of 
PLC/PRF/5 cell line. 
Exponentially growing PLC/PRF/5 cells were treated with ZD1839 (0，1， 
5 and 10 juM) for 72 hr before applying a single fraction of superficial 
X-irradiation at graded doses (0，1，2, 4 and 6 Gy) to corresponding flask 
in each group. Cells were immediately trypsinized, counted and replated 
with medium containing ZD1839. Following 10-day incubation interval, 
colonies were stained with 1% crystal violet. Only colonies formed with 
more than 50 cells were scored. Data in ZD1839/radiation treatment 
group were normalised by respective ZD1839 control, and were 
averaged from triplicate wells and duplicated experiments 士 S.E. 
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4.5 Immunohistochemical Analysis 
In order to examine whether ZD 1839 could arrest the cells at Go and early G\ 
phases, HCC cells were treated with ZD 1839 for 72 hr and cell cycle progression 
was evaluated by immunohistochemistry (Fig. 4.19-4.20). Exposure to ZD 1839 
resulted in 29% decrease of PLC/PRF/5 cells expressing Ki-67 antigen, indicating an 
increase in the proportion of PLC/PRF/5 cells in Go and early Gi phases, whereas 
only 2-5% incline in Go and early Gi phases was detected in all other four HCC cell 
y 
lines upon treatment with ZD 1839 (Table 4.3). 
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Fig. 4.19 Immimohistochemical Ki-67 staining of (a) HepSB, (b) SNU-387, and (c) 
SNU-423 cell lines after 72 hr incubation of ZD 1839. 
Exponentially growing HCC cells were treated with 0 fjM (left) or 10 juM 
(right) ZD1839 for 72 hr before fixation and agar block processing. The 
blocks were cut into sections and subjected to antigen retrieval, followed by 
incubation with monoclonal anti-Ki-67 antibodies. Photos of Ki-67 staining 
were taken under a 200X microscope. 
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Fig. 4.20 Immunohistochemical Ki-67 staining of (a) SNU-449 and (b) PLC/PRF/5 
cell lines after 72 hr incubation of ZDl 839. 
Exponentially growing HCC cells were treated with 0 fjM (left) or 10 juM 
(right) ZD1839 for 72 hr before fixation and agar block processing. The 
blocks were cut into sections and subjected to antigen retrieval, followed by 
incubation with monoclonal anti-Ki-67 antibodies. Photos of Ki-67 staining 
were taken under a 200X microscope. 
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Table 4.3 Effect of ZD 1839 on cell cycle distribution in the Go and early Gi phases 
of HCC cells upon 72 hr incubation. 
Cell lines Concentration Individual average % of Average % of Increased % of 
of ZD1839 Ki67-stained cells Ki67-stained HCC cells in 
(L^M) Observer 1 Observer 2 cells G q / G i phase 
Hep3B 0 77.06 78.04 77.55 
10 72.59 73.26 72.92 4.62 
SNU-387 0 82.60 85.78 84.19 
10 83.01 81.40 82.20 1.98 
SNU-423 0 84.76 85.84 85.30 
10 78.96 80.41 79.68 5.61 
SNU-449 0 82.20 81.93 82.06 
10 78.27 76.12 77.20 4.87 
PLC/PRF/5 0 84.63 84.41 84.52 
10 55.72 54.69 55.21 29.31 
Exponentially growing HCC cells were treated with 0 FJM or 10 /JM ZD1829for 72 hr 
before fixation and agar block processing. The blocks were cut into sections and 
pressure-cooked to perform antigen retrieval, followed by incubation with 
monoclonal anti-Ki-67 antibodies. Retained staining in both nuclei and nucleolus was 
considered as positive. Cells were examined in at least four areas and more than 1250 
HCC cells were analyzed for each session. 





5.1 Important Findings 
All five HCC cell lines had EGFR and HER2 protein expression. ZD 1839 could 
inhibit HCC cell growth, in which IC50 values of ZD 1839 against SNU-423 and 
PLC/PRF/5 cells were approximately 2-fold lower as compared with those against 
other three cell lines. No mutation was found within TK domains of EGFR (exons 
18-21) and HER2 (exons 18-24) in any of the five cell lines. Pre-exposure and 
continuous exposure to ZD 1839 in combination with a single-dose ionizing radiation 
(0, 1, 2, 4, and 6 Gy) did not enhance radiation response of HCC cell lines. 
Proportion of PLC/PRF/5 cells accumulated in Go and early Gi phases was increased 
by 29% upon incubation with ZD 1839, whereas other four cell lines demonstrated 
2-5% incline of growth arrest in Go and early Gi phases. 
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5.2 EGFR Expression of HCC Cells 
Previous studies showed EGFR expression level in tumors was variable 
(Moasser et al, 2001; Naruse et al., 2002; Stea et aL, 2003; Ono et aL, 2004), thus it 
was important to ensure EGFR expression in HCC cells prior to examining EGFR 
activity. Our findings showed all five HCC cell lines expressed EGFR protein, but 
the expression level was less than that of the positive control cell line A431. Analysis 
of EGFR expression in six HCC cell lines conducted by Carlin and colleagues (1988) 
0 
demonstrated the six HCC cell lines expressed EGFR protein at a density around 1 x 
10)5 molecules per cell, while the A431 cell line expressed 20-fold more receptors per 
cell. 
EGFR plays an important role in mediating cell differentiation, growth, 
adhesion, migration and metastasis (Yarden & Sliwkowski 2001; Woodbum 1999; 
Jorissen et al., 2003). The use of ZD 1839 is expected to inhibit growth of the cell 
lines used in this experiment. 
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5.3 Cytotoxicity of ZD1839 on HCC Cell Lines 
The effect of ZD 1839 on HCC cell growth was determined by MTT assay. We 
found that ZD 1839 inhibited cell growth in a dose-dependent manner with IC50 
values ranged from 7 |iM to 28 jiM in five HCC cell lines. Sensitivity of SNU-423 
and PLC/PRF/5 cells to ZD 1839 was particularly higher. This observation was 
similar to recent study on the effect of ZD 1839 in eight human esophageal carcinoma 
cell lines, in which the IC50 values ranged between 5.7 |iM and 36.9 jiM after a 72-hr 
incubation of ZD 1839 (Taira et al., 2006)�Upon a 72-hr exposure of nine human 
NSCLC cell lines to ZD 1839, the IC50 values of ZD 1839 against these cell lines 
ranged from 4 jjM to 42 jiM as measured by MTS assay (Ono et al., 2004). In 
another set of seven human NSCLC cell lines, the smallest IC50 value of ZD 1839 
toward these cell lines was 4.7 pM whereas the greatest one was 41.0 i^M subsequent 
to a 6-day ZD 1839 treatment (Amann et al., 2005). 
Nevertheless, the growth inhibition effect of ZD 1839 was not as effective as 
that of doxorubicin, a standard cytotoxic drug for HCC. Regard to our previous study 
assessing cytotoxic effects of several drugs on HCC cell lines (Choi et al., 2006), the 
IC50 values of doxorubicin against the five HCC cell lines were 23- to 400-fold 
smaller when compared with that of ZD1839 (Table 5.1). Therefore, ZD 1839 is 
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m u c h less cytotoxic when compared with chemotherapy. 
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Table 5.1 IC50 values of ZD1839 and doxorubicin against five HCC cell lines after 
72- hr incubation. 
Cell line ZD 1839 IC50 (^M) Doxorubicin IC50 ([iMf 
Hep3B 21.080 土 2.083 0.046 士 0.002 
SNU-387 28.197 ±2.993 0.220 土 0.014 
SNU-423 10.688 土 0.799 0.109 ±0.007 
SNU-449 14.007 ±0.724 0.603 土 0.018 
PLC/PRF/5 7.002 士 0.959 0.056 土 0.004 
IC50 value was defined as the concentration of drugs inhibiting HCC cell growth by 
50% after 72-hr incubation based on the dose-response curve. Each value was the 
mean concentration 土 S.D. of 3 independent experiments, 
a Data from previous study by Choi et al, 2006. 
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5.4 Factors Affecting the Cytotoxicity of ZD1839 
5.4.1 Effect of EGFR Expression on ZD 1839 Cytotoxicity 
The degree of sensitivity to ZD 1839 was not positively correlated to the 
magnitude of EGFR expression. SNU-423 and PLC/PRF/5, the cell lines with low 
IC50 values, had lower EGFR protein expression than other cell lines. This finding 
was consistent with other studies showing that EGFR expression level alone was not 
sufficient to determine sensitivity toward ZD 1839 (Moasser et al., 2001; Huang et al., 
2002; Campiglio et al” 2004; Hirata et al., 2005). In a panel of six human breast 
cancer cell lines, Campiglio et al (2004) found MDA-MB-231 cells with high level 
of EGFR expression was not responsive to ZD1839 (IC50 > 25 |iM) whereas 
MDA-MB-453 and MDA-MB-175 cells expressing low level of EGFR were 
responsive to ZD 1839 (IC50 was 6.5 ]xM and 0.17 jiM respectively). Likewise, Huang 
et al. (2002) provided evidence that a human H&N cancer cell line, SCC-13Y, 
possessing the lowest EGFR expression among cell lines tested was the most 
sensitive cell line toward ZD 1839. Our findings are first to show the lack of 
correlation between EGFR expression level and ZD 1839 sensitivity in HCC cell 
lines. 
5.4.2 Effect of EGFR Mutations on ZD 1839 Cytotoxicity 
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A human lung adenocarcinoma cell line H3255 has mutation at TK domain of 
EGFR and was highly sensitive to ZD 1839 (Paez et al., 2004). Lynch et al. (2004) 
also revealed that transfected mutant EGFR was more sensitive to ZD 1839 than the 
wild-type receptor. Moreover, patients with mutations in TK domain of EGFR gene 
had dramatic responses to ZD 1839 (Lynch et al., 2004; Paez et al., 2004). There is 
only limited data on EGFR mutation in HCC. In a study conducted by Su et al. 
(2005), no mutation within TK domain of EGFR was detected in a panel of 89 
resected primary HCC tissues. We sequenced exons 18-21 coding TK domain of the 
EGFR gene in all five HCC cell lines and found no mutation within TK domain of 
EGFR. Higher sensitivity of SNU-423 and PLC/PRF/5 cells toward ZD 1839 is not 
explained by EGFR TK domain mutation. 
5.4.3 Effect of HER2 Expression on ZD 1839 Cytotoxicity 
In vitro studies suggested that HER2-overexpressing cells were more sensitive 
to ZD 1839 than non-overexpressing ones (Moulder et al., 2001; Campiglio et al., 
2004; Hirata et al., 2005). Human breast cancer cell lines overexpressing HER2 were 
more sensitive to ZD 1839，in which the IC50 value of ZD 1839 was associated with 
HER2-overexpression in tumor cell lines (Moasser et al, 2001). Ito et al. (2001) 
showed that about 20% of tumor samples from HCC patients expressed HER2 
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protein at a higher level than their corresponding noncancerous ones. HER2 could 
represent a valuable co-target in modulating sensitivity of HCC cells to ZD 1839. 
Western blot analysis was conducted to detect HER2 protein expression in HCC cells. 
Despite the presence of a 185-kDa HER2 protein, HER2-overexpression was not 
observed. HER2 expression in SNU-387 and PLC/PRF/5 cells was less as compared 
to Hep3B and SNU-449 cells. We speculated that the relatively lower expression 
level of HER2 in HCC cells might reduce hetero-dimerization between EGFR and 
HER2. Thus, the higher sensitivity of SNU-423 and PLC/PRF/5 cells to ZD 1839 
cannot be accounted by HER2 overexpression. 
5.4.4 Effect of HER2 Mutations on ZD1839 Cytotoxicity 
HER2 mutation may affect tumor cell response to ZD 1839. Upon sequencing 
the entire coding sequence of the HER2 gene in 120 primary lung tumors, Stephens 
et al. (2004) found 4% samples contained mutations within TK domain. Another 
study demonstrated that 11% of HCC contained somatic H878Y missense mutations 
in exon 21 of HER2 and changed a basic residue to an acidic residue (Bekaii-Saab et 
al, 2005). Bekaii-Saab et al (2005) suggested that the somatic change may directly 
affect HER2 function. We sequenced exons 18-24 within TK domain of HER2 in the 
five HCC cell lines and found no mutation within this region. Great treatment 
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response in SNU-423 and PLC/PRF/5 cell lines does not appear to be caused by 
HER2 gene mutation. 
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5.5 Radiation Response ofHCC Cell Lines upon ZD1839 Treatment 
Solomon et al. (2003) evaluated the effect of ZD 1839 on radiosensitivity of 
human SCC in vitro and in vivo. Reduction in clonogenic survival and tumor growth 
delay were observed by combining ZD 1839 and radiation treatments (Solomon et al., 
2003). Other EGFR blockade, either by anti-EGFR mAb or TKI, conferred 
radiosensitization effect in various human cancer cells including colon, breast and 
lung adenocarcinoma (Wollman et al., 1994; Bianco et al., 2000; Bianco et al., 2002; 
/ 
Gupta et al, 2002). We investigated the effect of ZD 1839 treatment on radiation 
response of HCC cell lines by clonogenic survival assay. There was no obvious 
difference in survival fraction of the ZD 1839-pre-treated HCC cells when compared 
with radiation alone. The findings confirmed the lack of radio sensitizing effect. 
Solomon et al (2003) showed ZD 1839 pre-treatment on human vulvar 
carcinoma A431 cells did not enhance radiosensitivity while a prolonged exposure of 
the cancer cells to ZD 1839 led to a reduction of clonogenic survival. We also studied 
the effect of ZD 1839 continuous treatment by replating HCC cells in medium 
containing the corresponding concentrations of ZD 1839. Nonetheless, there was no 
significant difference in survival fraction of the treated cells when compared with 
radiation alone. We concluded that ZD 1839 cannot radiosensitize HCC cell lines. 
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5.6 Factors Affecting Radiation Response of ZD1839-treated HCC Cell Lines 
5.6.1 Effect of Growth Arrest on Radiation Response of HCC Cell Lines 
We explored the underlying mechanism for the negative result. Treatment with 
ZD 1839 is known to cause growth arrest in various human cancer cells including oral, 
lung and SCC (Bianco et al, 2002; Huang et al., 2002; Shintani et al, 2003; 
Solomon et aL, 2003; Hirata et al., 2005). Huang et al (2002) reported human H&N 
cancer cell lines, SCC-1 and SCC-13Y，incubating with 1 jj<M ZD1839 showed an 
/ 
increase in accumulation of cells in Go and Gi phases. A similar effect of ZD 1839 on 
cell cycle distribution was obtained in human vulvar cancer cell line A431 (Solomon 
et al., 2003). This accumulation of cells in Go and Gi phases may explain the lack of 
radiosensitization in HCC cells. This phase has been identified to be more resistant to 
radiation than other phases of the cell cycle (Hall, 2000). In this study, we found that 
ZD 1839 treatment resulted in 29% increase in accumulation of PLC/PRF/5 cells in 
Go and early Gi phases but the other four HCC cell lines demonstrated only 2-5% 
increase in growth arrest. This result implied the Go and early Gi phase growth arrest 
cannot be the only reason for the lack of radiosensitization in HCC cell lines. 
5.6.2 Other Factors Affecting Radiation Response of HCC Cell Lines 
Radiation fraction may affect treatment outcome. Multiple fractions of radiation 
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upon ZD 1839 incubation in a human vulvar cancer cell line A431 caused a 20 % 
greater reduction in cell number comparing to single fraction (Solomon et al, 2003). 
Cell kill by fractionated radiotherapy combined with ZD 1839 in human LoVo 
colorectal xenografts was enhanced by 7% (Williams et al., 2002). The basis of this 
increase in cell killing effect by fractionated radiotherapy might be related to EGFR 
inhibition, in which, the accelerated repopulation of tumor cells was reduced after 
each radiation (Williams et al., 2002; Solomon et al., 2003). Single fraction of 
radiation used in this study might explain the negative findings. 
Time lapse after exposure to ZD 1839 prior to radiation was critical. Short 
time-lapse of glioblastoma U251 cells with ZD 1839 ranging from 5 min to 60 min 
caused radiosensitization, while long pre-treatment with ZD 1839 (24 hr) resulted in 
radioprotective effect (Stea et al., 2003). Incubation with ZD 1839 for 72 hr before 
radiation treatment in this clonogenic assay study might contribute to no apparent 
radiosensitization effect in HCC cells. 
Radiation caused an increase in TGF-a, which is responsible for the secondary 
activation of EGFR and MAP-K pathways (Dent et al, 1999). This is supported by 
study in which addition of TGF-a neutralizing antibody to medium from irradiated 
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mammary carcinoma cells (MDA-TRl5-EGFR-CD533) and vulvar carcinoma cells 
(A431 -TR25-EGFR-antisense) abolished the secondary activation of EGFR and 
MAP-K cascades (Dent et al., 1999). After irradiation, the proliferation ability of 
tumor cells became MAP-K dependent since the irradiated cells treated with 
MEKl/2, an upstream of MAP-K, inhibitor exhibited dramatically reduced 
clonogenic survival (Dent et al., 1999). Moreover, inhibition of the activity of TGF-a 
or MEKl/2 before irradiation enhanced the ability of radiation to kill tumor cells, 
indicating that radiation-induced TGFa-EGFR-MAPK activation played an important 
role in promoting growth of tumor cells after irradiation (Dent et al., 1999). Moasser 
et al (2001) and Hirata et al. (2005) exhibited that ZD1839 treatment in human 
breast cancer and NSCLC cell lines resulted in a dose-dependent decline of Akt 
phosphorylation whereas no down-regulation on MAP-K activation was found. 
ZD 1839 could only inhibit PI3-K pathway activity but not MAP-K pathway activity 
(Moasser et al., 2001; Hirata et al., 2005). This mechanism might account for the 
negative result of enhancing radiation response in HCC cells. 
The negative outcome in this study should be explained by the schedule of the 
EGFR inhibition and alternative receptor-signaling pathways that could drive 
radioresistance upon EGFR blockade. In a study of two primary glioblastoma cell 
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lines expressing equivalent expression of total EGFR and phosphor-EGFR under 
basal conditions, inhibition of EGFR by AG 1478，an EGFR TKI, caused a marked 
increase in spontaneous and radiation-induced apoptosis in GMBs cell line but not in 
G M B r cell line (Chakravarti et al., 2002). This latter cell line was found to express 
insulin-like growth factor receptor (IGFR)-l, in which AG 1478 treatment led to 
increased level of IGFR-1 and phosphor-IGFR-1, suggesting a possible 
compensatory response upon EGFR blockade. 





ZD 1839 inhibits HCC cell growth in a dose-dependent manner. All five HCC 
cell lines possess EGFR and HER2 protein expression but there is no mutation within 
TK domains of EGFR and HER2. The higher sensitivity of SNU-423 and 
PLC/PRF/5 cells to ZD 1839 is not related to (i) the protein expression of EGFR, (ii) 
the somatic mutation in TK domain of EGFR, (iii) the protein expression of HER2 
and, (iv) the somatic mutation in TK domain of HER2. EGFR inhibition by ZD 1839 
does not radiosensitize HCC cell lines. The increase in tumor cells arrested at Go and 
early Gi phases upon ZD 1839 treatment offer only a partial explanation for this 
observation. Specific investigations are required to evaluate the possible role of other 
factors and/or alternative signaling pathways contributing to radiosensitization in 
HCC cell lines. Such knowledge would provide a rationale for optimal combinations 
between anti-EGFR drugs and ionizing radiation in HCC. 
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